Arbutus Biopharma Corp (ABUS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 70M 140M 210M Q3 '16: 14.4M Q4 '16: 1.5M Q1 '17: 1.1M Q2 '17: 1.9M Q3 '17: 8M Q4 '17: 10.7M Q1 '18: 11.9M Q2 '18: 12.1M Q3 '18: 6.8M Q4 '18: 5.9M Q1 '19: 5.2M Q2 '19: 4.6M Q3 '19: 6.1M Q4 '19: 6M Q1 '20: 6.8M Q2 '20: 7.7M Q3 '20: 6.1M Q4 '20: 6.9M Q1 '21: 7.5M Q2 '21: 8.4M Q3 '21: 10.2M Q4 '21: 11M Q1 '22: 21.5M Q2 '22: 33.4M Q3 '22: 36M Q4 '22: 39M Q1 '23: 33.1M Q2 '23: 23.5M Q3 '23: 22.2M Q4 '23: 18.1M Q1 '24: 13M Q2 '24: 10.1M Q3 '24: 6.7M Q4 '24: 6.2M Q1 '25: 6.4M Q2 '25: 15.4M Q3 '25: 14.6M Q4 '25: 14.1M Q1 '26: 191.4M Q2 '26: 181.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '16: -246M Q4 '16: -491.6M Q1 '17: -490M Q2 '17: -314.2M Q3 '17: -308.1M Q4 '17: -110.9M Q1 '18: -111M Q2 '18: -113.6M Q3 '18: -133.1M Q4 '18: -89.8M Q1 '19: -90.6M Q2 '19: -89.2M Q3 '19: -147.8M Q4 '19: -144M Q1 '20: -137.9M Q2 '20: -130.4M Q3 '20: -54.6M Q4 '20: -57.8M Q1 '21: -60.3M Q2 '21: -65.8M Q3 '21: -69M Q4 '21: -73.5M Q1 '22: -68.8M Q2 '22: -64.3M Q3 '22: -63.7M Q4 '22: -65.5M Q1 '23: -71.9M Q2 '23: -76.2M Q3 '23: -79.9M Q4 '23: -78.1M Q1 '24: -80.1M Q2 '24: -83.3M Q3 '24: -83.1M Q4 '24: -76.3M Q1 '25: -82.7M Q2 '25: -59.6M Q3 '25: -46.8M Q4 '25: -38.2M Q1 '26: 156.4M Q2 '26: 149M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -170.7M Q4 '16: -384.2M Q1 '17: -386.9M Q2 '17: -275.2M Q3 '17: -267.2M Q4 '17: -84.4M Q1 '18: -83.2M Q2 '18: -61.9M Q3 '18: -74.7M Q4 '18: -57.1M Q1 '19: -62.9M Q2 '19: -89.3M Q3 '19: -147.3M Q4 '19: -153.7M Q1 '20: -144.3M Q2 '20: -135.1M Q3 '20: -71.4M Q4 '20: -63.7M Q1 '21: -66.3M Q2 '21: -71.6M Q3 '21: -72M Q4 '21: -76.2M Q1 '22: -75.6M Q2 '22: -70.4M Q3 '22: -68.8M Q4 '22: -69.5M Q1 '23: -70M Q2 '23: -72.9M Q3 '23: -75.5M Q4 '23: -72.8M Q1 '24: -74.4M Q2 '24: -77.1M Q3 '24: -76.7M Q4 '24: -69.9M Q1 '25: -76.6M Q2 '25: -54.3M Q3 '25: -42.3M Q4 '25: -33.5M Q1 '26: 160.7M Q2 '26: 153.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '16: -61.3M Q4 '16: -57.9M Q1 '17: -63.9M Q2 '17: -52.1M Q3 '17: -53.1M Q4 '17: -48.6M Q1 '18: -51.1M Q2 '18: -63.6M Q3 '18: -61.1M Q4 '18: -67.9M Q1 '19: -64.5M Q2 '19: -64.5M Q3 '19: -74.7M Q4 '19: -71M Q1 '20: -69.9M Q2 '20: -61.1M Q3 '20: -49.8M Q4 '20: -51.4M Q1 '21: -53.9M Q2 '21: -59.1M Q3 '21: -62.9M Q4 '21: -67.5M Q1 '22: -29M Q2 '22: -35.3M Q3 '22: -38M Q4 '22: -35.4M Q1 '23: -83.3M Q2 '23: -82.5M Q3 '23: -85.6M Q4 '23: -85.9M Q1 '24: -77.9M Q2 '24: -72.9M Q3 '24: -71.8M Q4 '24: -64.8M Q1 '25: -58.9M Q2 '25: -60.2M Q3 '25: -45.3M Q4 '25: -39.6M Q1 '26: -34.4M Q2 '26: -24.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q1 '16: -51.4M Q2 '16: -52.1M Q3 '16: -63.8M Q4 '16: -61.9M Q1 '17: -71M Q2 '17: -61.5M Q3 '17: -62.8M Q4 '17: -55.9M Q1 '18: -55.2M Q2 '18: -65M Q3 '18: -62.2M Q4 '18: -69M Q1 '19: -65.4M Q2 '19: -65.2M Q3 '19: -75.5M Q4 '19: -71.6M Q1 '20: -70.4M Q2 '20: -61.5M Q3 '20: -49.9M Q4 '20: -51.7M Q1 '21: -54.2M Q2 '21: -60M Q3 '21: -63.8M Q4 '21: -68.3M Q1 '22: -29.8M Q2 '22: -35.7M Q3 '22: -38.4M Q4 '22: -35.9M Q1 '23: -83.8M Q2 '23: -83.7M Q3 '23: -86.8M Q4 '23: -86.9M Q1 '24: -78.9M Q2 '24: -73M Q3 '24: -71.9M Q4 '24: -65M Q1 '25: -59M Q2 '25: -60.3M Q3 '25: -45.4M Q4 '25: -39.6M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '14: 19.8M Q1 '15: 30.2M Q2 '17: 54.6M Q2 '18: 56.5M Q2 '19: 56.8M Q1 '20: 67.7M Q2 '20: 69.6M Q3 '20: 79.5M Q1 '21: 93.4M Q2 '21: 96.9M Q3 '21: 101.3M Q1 '22: 148.4M Q2 '22: 148.8M Q3 '22: 151M Q1 '23: 161.6M Q2 '23: 166.1M Q3 '23: 167.5M Q1 '24: 175.6M Q2 '24: 188M Q3 '24: 189M Q1 '25: 190.7M Q2 '25: 192.4M Q3 '25: 191.8M Q1 '26: 195.2M Q2 '26: 197.5M Q1 '14 Q2 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '15: -1.51 Q4 '15: -1.34 Q1 '16: -1.25 Q2 '16: -3.45 Q3 '16: -3.25 Q4 '16: -7.20 Q1 '17: -7.23 Q2 '17: -5.09 Q3 '17: -4.93 Q4 '17: -1.55 Q1 '18: -1.57 Q2 '19: -1.80 Q3 '19: -2.81 Q4 '19: -2.89 Q1 '20: -2.67 Q2 '20: -2.46 Q3 '20: -1.23 Q4 '20: -1.00 Q1 '21: -0.96 Q2 '21: -0.94 Q3 '21: -0.91 Q4 '21: -0.83 Q1 '22: -0.73 Q2 '22: -0.60 Q3 '22: -0.48 Q4 '22: -0.47 Q1 '23: -0.46 Q2 '23: -0.46 Q3 '23: -0.46 Q4 '23: -0.44 Q1 '24: -0.44 Q2 '24: -0.45 Q3 '24: -0.43 Q4 '24: -0.38 Q1 '25: -0.41 Q2 '25: -0.29 Q3 '25: -0.23 Q4 '25: -0.17 Q1 '26: 0.83 Q2 '26: 0.79 Q3 '16 Q4 '17 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.